Atara Biotherapeutics, Inc.

LSE:0HIY Stock Report

Market Cap: US$65.7m

Atara Biotherapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

LSE:0HIY Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
18 Nov 24SellUS$15,274Eric HyllengrenIndividual1,364US$11.20
18 Nov 24SellUS$11,198Jill HenrichIndividual1,000US$11.20
18 Nov 24SellUS$18,633Anhco NguyenIndividual1,664US$11.20
16 Aug 24SellUS$6,384Jill HenrichIndividual963US$6.63
16 Aug 24SellUS$7,677K. MuruganIndividual1,158US$6.63
16 Aug 24SellUS$7,093Eric HyllengrenIndividual1,070US$6.63
16 Aug 24SellUS$12,072Anhco NguyenIndividual1,821US$6.63
16 Aug 24SellUS$20,139Pascal TouchonIndividual3,038US$6.63
22 May 24BuyUS$6,372,079Adiumentum Capital ManagementCompany322,636.92US$19.75
16 May 24SellUS$15,888Jill HenrichIndividual1,030US$15.43
16 May 24SellUS$17,676Eric HyllengrenIndividual1,145.92US$15.43
16 May 24SellUS$26,469Anhco NguyenIndividual1,715.96US$15.43
16 May 24SellUS$19,991K. MuruganIndividual1,296.04US$15.43
16 May 24SellUS$50,289Pascal TouchonIndividual3,260.24US$15.43
04 Mar 24SellUS$2,793Jill HenrichIndividual155.16US$18.00
04 Mar 24SellUS$17,888Pascal TouchonIndividual993.76US$18.00
04 Mar 24SellUS$4,810Eric HyllengrenIndividual267.16US$18.03
04 Mar 24SellUS$7,232K. MuruganIndividual401.76US$18.00
04 Mar 24SellUS$7,737Anhco NguyenIndividual429.84US$18.00

Insider Trading Volume

Insider Buying: 0HIY insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of 0HIY?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders128,5692.23%
Hedge Funds945,73316.4%
General Public1,932,31533.5%
Institutions2,753,13347.8%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 41.3%.

Top Shareholders

Top 25 shareholders own 65.13% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
19.7%
Adiumentum Capital Management
1,133,823US$12.9m251%no data
8.57%
EcoR1 Capital, LLC
493,463US$5.6m21.3%0.17%
7.85%
Redmile Group, LLC
452,270US$5.2m0%0.25%
4.52%
Citadel Advisors LLC
260,480US$3.0m0%no data
3.54%
Bank of America Corporation, Asset Management Arm
203,617US$2.3m9.47%no data
3.14%
The Vanguard Group, Inc.
180,715US$2.1m6.72%no data
3.06%
Millennium Management LLC
176,053US$2.0m50.9%no data
2.24%
Acadian Asset Management LLC
129,144US$1.5m8.19%no data
2.16%
Vestal Point Capital, LP
124,677US$1.4m11.3%0.1%
1.31%
Tang Capital Management, LLC
75,196US$857.2k0%0.06%
1.3%
Kleiner Perkins Caufield & Byers
75,066US$855.8k0%0.18%
1.18%
Renaissance Technologies LLC
67,734US$772.2k47%no data
1.06%
BlackRock, Inc.
60,954US$694.9k-0.31%no data
0.81%
Geode Capital Management, LLC
46,720US$532.6k9.47%no data
0.75%
Centiva Capital, LP
43,403US$494.8k-69.1%0.02%
0.69%
Staley Capital Advisers, Inc.
40,000US$456.0k0%0.02%
0.49%
Pascal Touchon
28,339US$323.1k22.4%no data
0.45%
Charles Schwab Investment Management, Inc.
26,155US$298.2k0%no data
0.43%
FMR LLC
25,000US$285.0k41.9%no data
0.39%
State Street Global Advisors, Inc.
22,353US$254.8k52.3%no data
0.35%
Eric Dobmeier
20,253US$230.9k0%no data
0.33%
Anhco Nguyen
18,811US$214.4k51.7%no data
0.29%
Carol Gallagher
16,904US$192.7k0%no data
0.28%
Morgan Stanley, Investment Banking and Brokerage Investments
16,149US$184.1k66.8%no data
0.24%
Bridgeway Capital Management, LLC
14,000US$159.6k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 07:20
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Atara Biotherapeutics, Inc. is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John NewmanCanaccord Genuity
Yigal NochomovitzCitigroup Inc
Jonathan MillerEvercore ISI